The U.S. FDA approved the New Drug Application of Xelpros 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Zymeworks Announces Antibody Fc Engineering Collaboration and License Agreement with GSK
Autoimmune, Autoimmune Disease, Autoimmune Diseases, Bi-Specific Antibodies, Biotherapeutics, Business, Collaboration, Collaborations, Health, Immune Response, Inflammatory Diseases, Licensing, Licensing, Monoclonal Antibodies, Monoclonal Antibodies, Oncology, R&D, TechnologyVANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. today announced that it has entered into a collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal […]
LOUISVILLE, CO–(Marketwired – August 04, 2015) – GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively license GI-6207, […]
By Denise Roland The Wall Street Journal Biography @deniseroland [email protected] Updated July 30, 2015 7:51 a.m. ET AstraZeneca PLC on Thursday reported an increase in second-quarter revenue, thanks to proceeds […]
